Details of Disease

General Information of Disease (ID: DISKW8PI)

Disease Name	Acne vulgaris
Synonyms	acne, adult; frontalis acne; acne; acne (disease); acne varioliformis; acne vulgaris
Disease Class	ED80: Acne vulgaris
Definition	An inflammatory process of the sebaceous glands which is characterized by comedones, nodules, papules and/or pustules on the skin.
Disease Hierarchy	DIS8UM81: Sebaceous gland disease DISY5SZC: Dermatitis DISSCALK: Hereditary skin disorder DISKW8PI: Acne vulgaris
ICD Code	ICD-11 ICD-11: ED80 ICD-10 ICD-10: L70.0 ICD-9 ICD-9: 706.1 Expand ICD-9 706.1
Disease Identifiers	MONDO ID MONDO_0011438 MESH ID D000152 UMLS CUI C0702166 MedGen ID 152379 HPO ID HP:0001061 SNOMED CT ID 11381005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 39 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adapalene	DMX2358	Approved	Small molecular drug	[1]
Aminolevulinic acid hci	DMS4BLQ	Approved	Small molecular drug	[2]
Amphotericin B	DMTAJQE	Approved	Small molecular drug	[3]
Azelaic Acid	DMHVL0J	Approved	Small molecular drug	[4]
Benzoyl peroxide	DMSTW1Q	Approved	Small molecular drug	[5]
Clascoterone	DMPGR1E	Approved	Small molecular drug	[6]
Clindamycin	DM15HL8	Approved	Small molecular drug	[5]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[7]
Dapsone	DM4LT8A	Approved	Small molecular drug	[8]
Demeclocycline	DMZEPFJ	Approved	Small molecular drug	[5]
Doxycycline	DM7ICNU	Approved	Small molecular drug	[9]
Drospirenone	DM1A9W3	Approved	Small molecular drug	[10]
Efalith	DMZMK8R	Approved	NA	[5]
Erythromycin	DM4K7GQ	Approved	Small molecular drug	[11]
Estradiol	DMUNTE3	Approved	Small molecular drug	[12]
Estrone	DM5T6US	Approved	Small molecular drug	[13]
Ethinyl Estradiol	DMODJ40	Approved	Small molecular drug	[14]
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[15]
Green soap	DMOEI2X	Approved	NA	[5]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[16]
Isotretinoin	DM4QTBN	Approved	Small molecular drug	[17]
Methyl aminolevulinate	DMIUX3D	Approved	Small molecular drug	[18]
Minocycline	DMVN5OH	Approved	Small molecular drug	[19]
Nadifloxacin	DMY24S0	Approved	Small molecular drug	[5]
Nicotinamide	DMUPE07	Approved	Small molecular drug	[20]
Norethindrone	DMTY169	Approved	Small molecular drug	[21]
Norgestimate	DMYP4XC	Approved	Small molecular drug	[22]
Promestriene	DMU92F8	Approved	Small molecular drug	[5]
Riboflavin	DM8YMWE	Approved	Small molecular drug	[23]
Rolitetracycline	DMBR5Q7	Approved	Small molecular drug	[24]
Salicyclic acid	DM2F8XZ	Approved	Small molecular drug	[25]
Sarecycline	DMLZNIQ	Approved	NA	[26]
Sucralfate	DMP9HBO	Approved	NA	[27]
Sulfacetamide	DMZ6VEY	Approved	Small molecular drug	[28]
Tazarotene	DM8SMD1	Approved	Small molecular drug	[29]
Tetracycline	DMZA017	Approved	Small molecular drug	[30]
Tretinoin	DM49DUI	Approved	Small molecular drug	[31]
Trifarotene	DMOL793	Approved	Small molecular drug	[32]
Zinc hyaluronate	DMZ3BNF	Approved	NA	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 39 Drug(s)

This Disease is Treated as An Indication in 43 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DFD-03	DMVE1US	Phase 3	NA	[33]
FMX101	DMUFO1J	Phase 3	NA	[33]
IDP-123	DM0YVMA	Phase 3	NA	[33]
LEO 43204	DMKMCP8	Phase 3	NA	[33]
MABp1	DM8D13S	Phase 3	NA	[33]
Omiganan	DM7UF9M	Phase 3	NA	[33]
SB204	DMSTCY3	Phase 3	NA	[33]
SNA-001	DMGTBJF	Phase 3	NA	[33]
Velac Gel	DMXHI89	Phase 3	NA	[34]
AcVx-25	DMDUBKP	Phase 2	NA	[35]
ADPS	DMB0ZV7	Phase 2	NA	[33]
AOB101	DMPDQSR	Phase 2	NA	[33]
ASCJ-9	DMMBVCJ	Phase 2	NA	[33]
BLI-1100	DMB0LLM	Phase 2	NA	[36]
BPX-01	DM9YW27	Phase 2	NA	[33]
BTX1503	DM7VF31	Phase 2	NA	[33]
CB-06-01	DM6OMJG	Phase 2	NA	[37]
CD-2475/101	DMYBBYR	Phase 2	NA	[38]
CJM112	DMTSVJM	Phase 2	NA	[39]
DMT310	DMHKJSS	Phase 2	NA	[33]
DPIV/CD26	DMXBCTE	Phase 2	NA	[40]
IDP-107	DMEG6M5	Phase 2	NA	[41]
IDP-120	DMZ27ZB	Phase 2	NA	[33]
IDP-126	DM11UWT	Phase 2	NA	[33]
ImCOOH	DMYIJ9M	Phase 2	NA	[42]
JNJ-10229570	DMY7Q3I	Phase 2	NA	[43]
Lemuteporfin	DMYAYNO	Phase 2	NA	[44]
NAI-acne	DM7P0WR	Phase 2	NA	[45]
PCL-016	DMYRIHZ	Phase 2	NA	[46]
PPA-904	DM3XHMT	Phase 2	NA	[47]
Radezolid	DMOI9EL	Phase 2	NA	[33]
RT-001	DM3FS1G	Phase 2	Small molecular drug	[48]
SIRS-T	DMURG0W	Phase 2	NA	[33]
TWIN	DMR9P7F	Phase 2	NA	[33]
VB 1953	DM0YWQ4	Phase 2	NA	[49]
WC-3018	DMQ46YQ	Phase 2	NA	[50]
XOMA-629	DMWEB07	Phase 2	NA	[51]
Drug 1940029	DM2CZ58	Phase 1	NA	[52]
IMD-0354	DMOFSLE	Phase 1	Small molecular drug	[53]
Metastat	DMTQ4PN	Phase 1	Small molecular drug	[54]
NB-003	DMHD7RO	Phase 1	NA	[55]
SL-017	DMVT1ND	Phase 1	NA	[56]
Sphingosine-1-phosphate	DMJCQKA	Phase 1	Small molecular drug	[57]
------------------------------------------------------------------------------------


⏷ Show the Full List of 43 Drug(s)

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMY-30123	DMMJDYI	Discontinued in Phase 2	Small molecular drug	[58]
MK-386	DM48ELZ	Discontinued in Phase 2	Small molecular drug	[59]
PF-275366	DMEMK6G	Discontinued in Phase 2	NA	[60]
AS-601811	DMINF80	Discontinued in Phase 1	Small molecular drug	[61]
BI-K0376	DM3CINO	Discontinued in Phase 1	NA	[62]
M-512101	DMV1UCP	Discontinued in Phase 1	NA	[63]
RU-58841	DMMEAZ2	Discontinued in Phase 1	Small molecular drug	[64]
VAG-624	DM4SGAN	Discontinued in Phase 1	NA	[65]
Ecalcidene	DMUR1FK	Terminated	Small molecular drug	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Seysara	DM7GFLZ	Application submitted	NA	[33]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DPC-1528	DMLPQ5F	Investigative	NA	[67]
HB-1345	DMY95LX	Investigative	NA	[67]
HO/04/09	DM4DTZQ	Investigative	NA	[67]
M-108101	DMUB47L	Investigative	NA	[67]
NLP-44	DMBQO7O	Investigative	NA	[67]
Sharon-4000	DM1GE10	Investigative	NA	[67]
VAL-001	DMML659	Investigative	NA	[67]
XGP-410	DMPA4YH	Investigative	NA	[67]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NLRP3	TT4EN8X	moderate	Genetic Variation	[69]
TLR2	TTY7ZHS	moderate	Biomarker	[70]
DEFB4A	TTIVY12	Strong	Biomarker	[71]
LYZ	TTAOZBW	Strong	Biomarker	[72]
NOD2	TTYPUHA	Strong	Biomarker	[73]
ANGPTL3	TT59GO7	Definitive	Altered Expression	[74]
CCR1	TTC24WT	Definitive	Biomarker	[75]
HDAC8	TTT6LFV	Definitive	Altered Expression	[76]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCD2	DT4MBHD	Definitive	Altered Expression	[77]
SLC9A6	DTN0JXW	Definitive	Genetic Variation	[78]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADHFE1	DE8RJ3F	Definitive	Biomarker	[79]
HSD17B3	DEX8J7E	Definitive	Genetic Variation	[80]
HSD3B1	DERDQWN	Definitive	Genetic Variation	[80]
------------------------------------------------------------------------------------

This Disease Is Related to 17 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
SEMA4A	OT8901H3	Limited	Biomarker	[81]
DCD	OTV5PBGJ	Strong	Altered Expression	[82]
DEFB1	OT5SV0E4	Strong	Biomarker	[71]
MEFV	OTRJ6S6K	Strong	Biomarker	[73]
PSTPIP1	OT4PGEAB	Strong	Biomarker	[73]
SMIM10L2B	OT04IG2N	Strong	Genetic Variation	[83]
APH1A	OT97F1TU	Definitive	Biomarker	[84]
CD79A	OTOJC8DV	Definitive	Biomarker	[85]
GNLY	OTZJKA8C	Definitive	Biomarker	[86]
IL18BP	OTW0LRYZ	Definitive	Biomarker	[87]
LGALS7	OTMSVI7R	Definitive	Biomarker	[88]
NAP1L2	OT8QI4GF	Definitive	Biomarker	[89]
PSMD6	OTX59EGK	Definitive	Biomarker	[90]
RNASE7	OTIXO0Z4	Definitive	Altered Expression	[91]
RPS10	OTE3VSAH	Definitive	Biomarker	[90]
S100A7A	OTNM8DCP	Definitive	Altered Expression	[92]
SFPQ	OTLCIAPJ	Definitive	Biomarker	[84]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5429).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4784).
3	Amphotericin B FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7484).
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7	Cortisone acetate FDA Label
8	Dapsone FDA Label
9	Doxycycline FDA Label
10	Drospirenone FDA Label
11	Erythromycin FDA Label
12	Estradiol FDA Label
13	Estrone FDA Label
14	Ethinyl estradiol FDA Label
15	Curcumin/Fusidic Acid Bitherapy Loaded Mixed Micellar Nanogel for Acne Vulgaris Treatment: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2023 Sep 11;24(7):182.
16	Hydrocortisone FDA Label
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7600).
18	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021415.
19	Minocycline FDA Label
20	The role of nicotinamide in acne treatment. Dermatol Ther. 2017 Sep;30(5).
21	Norethindrone FDA Label
22	Norgestimate FDA Label
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6578).
24	Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16.
25	The influence of various factors on the human resident skin flora. Semin Dermatol. 1990 Dec;9(4):305-8.
26	Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18.
27	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7055).
28	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080028.
29	Tazarotene FDA Label
30	Tetracycline FDA Label
31	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2644).
32	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
33	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
34	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74.
35	Clinical pipeline report, company report or official report of NRVISION Ltd.
36	ClinicalTrials.gov (NCT01815450) BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris. U.S. National Institutes of Health.
37	Clinical pipeline report, company report or official report of Cassiopea.
38	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034061)
39	ClinicalTrials.gov (NCT02998671) Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne. U.S. National Institutes of Health.
40	ClinicalTrials.gov (NCT00824980) Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis. U.S. National Institutes of Health.
41	ClinicalTrials.gov (NCT00666900) A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris. U.S. National Institutes of Health.
42	ClinicalTrials.gov (NCT00583895) Safety and Efficacy Study of ImCOOH Cream in Patients Suffering From Moderate Atopic Dermatitis. U.S. National Institutes of Health.
43	ClinicalTrials.gov (NCT01326780) A Study of a New Drug Treatment for Acne. U.S. National Institutes of Health.
44	ClinicalTrials.gov (NCT00116571) Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS). U.S. National Institutes of Health.
45	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031008)
46	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016059)
47	ClinicalTrials.gov (NCT00825760) Clinical Trial to Investigate Treatment With Photodynamic Therapy to Reduce Levels of Bacteria in Leg Ulcers. U.S. National Institutes of Health.
48	ClinicalTrials.gov (NCT01124565) Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults. U.S. National Institutes of Health.
49	ClinicalTrials.gov (NCT03900676) Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris. U.S. National Institutes of Health.
50	Biopharmaceutical Research Companies Are Developing Nearly 300 Medicines to Treat Diseases of the Skin. Pharmaceutical Research and Manufacturers of America report. 2011
51	Clinical pipeline report, company report or official report of XOMA Ltd.
52	ClinicalTrials.gov (NCT01984801) Study to Investigate the Irritation Potential of GSK1940029 Gel. U.S. National Institutes of Health.
53	Activation of histamine H4 receptor inhibits TNFalpha/IMD-0354-induced apoptosis in human salivary NS-SV-AC cells. Apoptosis. 2014 Dec;19(12):1702-11.
54	ClinicalTrials.gov (NCT00001683) A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. U.S. National Institutes of Health.
55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031862)
56	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020104)
57	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 911).
58	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003321)
59	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006173)
60	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025650)
61	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013228)
62	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016879)
63	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016781)
64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005990)
65	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021812)
66	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019289)
67	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
68	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033829)
69	Genetic association between the NLRP3 gene and acne vulgaris in a Chinese population.Clin Exp Dermatol. 2019 Mar;44(2):184-189. doi: 10.1111/ced.13657. Epub 2018 Jun 11.
70	Establishment of an Anti-acne Vulgaris Evaluation Method Based on TLR2 and TLR4-mediated Interleukin-8 Production.In Vivo. 2019 Nov-Dec;33(6):1929-1934. doi: 10.21873/invivo.11687.
71	Comparison of Efficacy of Doxycycline and Isotretinoin on Cutaneous Human Beta-Defensin-1 and -2 Levels in Acne Vulgaris.Indian J Dermatol. 2018 Sep-Oct;63(5):380-385. doi: 10.4103/ijd.IJD_402_16.
72	Control of Propionibacterium acnes by natural antimicrobial substances: Role of thebacteriocin AS-48 and lysozyme.Sci Rep. 2018 Aug 6;8(1):11766. doi: 10.1038/s41598-018-29580-7.
73	Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation.Br J Dermatol. 2016 Nov;175(5):882-891. doi: 10.1111/bjd.14691. Epub 2016 Aug 23.
74	Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state.Prostaglandins Other Lipid Mediat. 2017 Jan;128-129:1-7. doi: 10.1016/j.prostaglandins.2016.12.001. Epub 2016 Dec 23.
75	Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice.J Natl Cancer Inst. 2004 Feb 4;96(3):201-9. doi: 10.1093/jnci/djh024.
76	Short-Chain Fatty Acids from Cutibacterium acnes Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes.J Immunol. 2019 Mar 15;202(6):1767-1776. doi: 10.4049/jimmunol.1800893. Epub 2019 Feb 8.
77	Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy.PLoS One. 2014 Jul 31;9(7):e103742. doi: 10.1371/journal.pone.0103742. eCollection 2014.
78	Nisin J, a Novel Natural Nisin Variant, Is Produced by Staphylococcus capitis Sourced from the Human Skin Microbiota.J Bacteriol. 2020 Jan 15;202(3):e00639-19. doi: 10.1128/JB.00639-19. Print 2020 Jan 15.
79	Characterisation and pure culture of putative health-associated oral bacterium BU063 (Tannerella sp. HOT-286) reveals presence of a potentially novel glycosylated S-layer.FEMS Microbiol Lett. 2018 Sep 1;365(17). doi: 10.1093/femsle/fny180.
80	Association of HSD17B3 and HSD3B1 polymorphisms with acne vulgaris in Southwestern Han Chinese.Dermatology. 2013;227(3):202-8. doi: 10.1159/000353581. Epub 2013 Oct 19.
81	Proliferative response of peripheral blood mononuclear cells and levels of antibody to recombinant protein from Propionibacterium acnes DNA expression library in Japanese patients with sarcoidosis.Sarcoidosis Vasc Diffuse Lung Dis. 2000 Oct;17(3):256-65.
82	Plasma dermcidin levels in acne patients, and the effect of isotretinoin treatment on dermcidin levels.Dermatol Ther. 2019 Sep;32(5):e13044. doi: 10.1111/dth.13044. Epub 2019 Aug 20.
83	Propionibacterium acnes susceptibility to low-level 449nm blue light photobiomodulation.Lasers Surg Med. 2019 Oct;51(8):727-734. doi: 10.1002/lsm.23087. Epub 2019 Mar 28.
84	A Microtube Array Membrane (MTAM) Encapsulated Live Fermenting Staphylococcus epidermidis as a Skin Probiotic Patch against Cutibacterium acnes.Int J Mol Sci. 2018 Dec 20;20(1):14. doi: 10.3390/ijms20010014.
85	Randomized controlled double-blind study of a cleanser composed of 5-aminolevulinic acid and peptides on mild and moderate acne vulgaris.J Cosmet Dermatol. 2020 Jul;19(7):1745-1750. doi: 10.1111/jocd.13232. Epub 2019 Nov 28.
86	Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibacterium acnes.J Invest Dermatol. 2005 Aug;125(2):256-63. doi: 10.1111/j.0022-202X.2005.23805.x.
87	IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice.J Immunol. 2001 Nov 15;167(10):5913-20. doi: 10.4049/jimmunol.167.10.5913.
88	Clinical significance of neutrophil gelatinase-associated lipocalin and galectin-7 in tape-stripped stratum corneum of acne vulgaris.J Dermatol. 2018 May;45(5):618-621. doi: 10.1111/1346-8138.14261. Epub 2018 Feb 22.
89	Treating Acne With Topical Antibiotics: Current Obstacles and the Introduction of Topical Minocycline as a New Treatment Option.J Drugs Dermatol. 2019 Mar 1;18(3):240-244.
90	Propionibacterium acnes is developing gradual increase in resistance to oral tetracyclines.J Med Microbiol. 2017 Jan;66(1):8-12. doi: 10.1099/jmm.0.000392.
91	Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris.Arch Dermatol Res. 2014 Oct;306(8):689-700. doi: 10.1007/s00403-014-1477-3. Epub 2014 Jun 11.
92	Downregulation of S100a7a antimicrobial peptide in acne vulgaris patients after isotretinoin therapy.Dermatol Ther. 2019 Nov;32(6):e13136. doi: 10.1111/dth.13136. Epub 2019 Oct 31.